12:00 AM
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

SMT C1100: Preliminary Phase I data

Top-line data from a double-blind, placebo-controlled, dose-escalation Phase I trial in 48 healthy volunteers showed that all doses of a nanoparticle aqueous suspension reformulation of oral SMT C1100 were well tolerated and met the primary safety endpoint. All subjects were within the normal limits for blood pressure, pulse rate, body temperature and 12-lead ECG data. Summit also said that the aqueous formulation improved absorption levels of the compound that...

Read the full 323 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >